APA (7th ed.) Citation

JP, N., C, S., D, Ö., MW, B., & CW, M. (2026). The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. The Lancet. Oncology, 27(1), e3. https://doi.org/10.1016/S1470-2045(25)00601-1

Chicago Style (17th ed.) Citation

JP, Neoptolemos, Springfeld C, Öhlund D, Büchler MW, and Michalski CW. "The PREOPANC-2 Trial in Resectable and Borderline Resectable Pancreatic Cancer." The Lancet. Oncology 27, no. 1 (2026): e3. https://doi.org/10.1016/S1470-2045(25)00601-1.

MLA (9th ed.) Citation

JP, Neoptolemos, et al. "The PREOPANC-2 Trial in Resectable and Borderline Resectable Pancreatic Cancer." The Lancet. Oncology, vol. 27, no. 1, 2026, p. e3, https://doi.org/10.1016/S1470-2045(25)00601-1.